Underuse of clozapine in treatment-resistant schizophrenia

Advances in Psychiatric Treatment

Volumn 17, Issue 4, 2011, Pages 250-255

  Mistry, Himanshu ^a   Osborn, David ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

AGRANULOCYTOSIS; CARDIOMYOPATHY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG USE; ETHNIC DIFFERENCE; HEALTH SURVEY; HUMAN; HYPERSALIVATION; LUNG EMBOLISM; MYOCARDITIS; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SAFETY; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PROFESSIONAL COMPETENCE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 79960098384     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.110.008128     Document Type: Review

References (56)

1. Aitchison KJ, Kerwin RW (1997) Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry 171: 125-30. (Pubitemid 27345143)
2. American Psychiatric Association (2004) Practice Guideline for the Treatment of Patients with Schizophrenia (2nd edn). American Psychiatric Publishing.
3. Angermeyer M, Loffler W, Muller P, et al (2001) Patients' and relatives' assessment of clozapine treatment. Psychological Medicine 31: 509-17. (Pubitemid 32294049)
4. Arranz M, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophrenia Bulletin 34: 1130-44.
5. Arranz M, Munro J, Birkett J, et al (2000) Pharmacogenetic prediction of clozapine response. Lancet 355: 1615-6. (Pubitemid 30240510)
6. Atkin K, Kendall F, Gould D, et al (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry 169: 483-8.
7. Bhugra D, Bhui K (1999) Ethnic and cultural factors in psychopharmacology. Advances in Psychiatric Treatment 5: 89-95.
8. Chaudhury IB, Neelam K, Duddu V, et al (2008) Ethnicity and psychopharmacology. Journal of Psychopharmacology 22: 673-80.
9. Cirulli G (2005) Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. Psychiatric Bulletin 29: 377-80.
10. Conley R, Kelly D (2001) Management of treatment resistant schizophrenia. Biological Psychiatry 50: 898-911.
11. Conley R, Kelly D, Lambert T, et al (2005) Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services 56: 320-3. (Pubitemid 40333565)
12. De Leon J (2009) Future (or lack of future) of personalised prescription in psychiatry. Pharmacological Research 59: 81-9.
13. Downs J, Zinkler M (2007) Clozapine: national review of postcode prescribing. Psychiatric Bulletin 31: 384-7. (Pubitemid 47565022)
14. Duggan A, Warner J, Knapp M, et al (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry 182: 505-8.
15. Essali A, Al-Haj Hassan N, Li C, et al (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1: CD000059.
16. Essock S, Hargreaves W, Dohm F, et al (1996) Clozapine eligibility among state hospital patients. Schizophrenia Bulletin 22: 15-25. (Pubitemid 26081407)
17. Fayek M, Flowers C, Signorelli D, et al (2003) Psychopharmacology: underuse of evidence base treatments in psychiatry. Psychiatric Services 54: 1453-6.
18. Haddy T, Rana S, Castro O (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? Journal of Laboratory and Clinical Medicine 133: 15-22. (Pubitemid 29032412)
19. Hayhurst K, Brown P, Lewis S (2002) The cost-effectiveness of clozapine: a controlled, population-based mirror-image study. Journal of Psychopharmacology 16: 169-75. (Pubitemid 34614887)
20. Hayhurst KP, Brown P, Lewis SW (2003) Postcode prescribing for schizophrenia. British Journal of Psychiatry 182: 281-3. (Pubitemid 36408274)
21. Hedgecoe A (2006) Context, ethics and pharmacogenetics. Studies in History and Philosophy of Biological and Biomedical Sciences 37: 566-82.
22. Hodge K, Jesperson S (2008) Side effects and treatment with clozapine: a comparison of the views of consumers and their clinicians. International Journal of Mental Health Nursing 17: 2-8.
23. Iqbal M, Rahman A, Husain Z, et al (2003) Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry 15: 33-48. (Pubitemid 36723639)
24. Kane J, Honigfeld G, Singer J, et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789-96.
25. Kelly D, Dixon L, Kreyenbuhl J, et al (2006) Clozapine utilization and outcomes by race in a public mental health system 1994-2000. Journal of Clinical Psychiatry 67: 1404-11. (Pubitemid 44583388)
26. Kelly D, Kreyenbuhl J, Buchanan R, et al (2007a) Why not clozapine? Clinical Schizophrenia and Related Psychosis 1: 92-5.
27. Kelly D, Kreyenbuhl J, Dixon L, et al (2007b) Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophrenia Bulletin 33: 1221-4. (Pubitemid 47347911)
28. Kerwin R, Munro J, O'Sullivan D (2000) Paradoxical pattern of haematological risk with clozapine. [Author's reply]. British Journal of Psychiatry 177: 88. (Pubitemid 30450677)
29. Kuno E, Rothbard A (2002) Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 159: 567-72. (Pubitemid 34274938)
30. Lawson WB (1996) Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacology Bulletin 32: 275-81.
31. Leucht S, Komossa K, Rummel-Kluge C, et al (2009) A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166: 152-63.
32. Lewis S, Barnes T, Davies L, et al (2006) Randomised controlled trial of effect of prescription of clozapine versus other second generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32: 715-23. (Pubitemid 44412859)
33. Lindstrom LH (1988) The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 77: 524-9.
34. Mallinger J, Fisher S, Brown T, et al (2006) Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatric Services 57: 133-6. (Pubitemid 43053850)
35. Mark T, Dirani R, Slade E, et al (2002) Access to new medications to treat schizophrenia. Journal of Behavioral Health Services and Research 29: 15-29. (Pubitemid 34150317)
36. McEvoy J, Lieberman J, Stroup T, et al (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163: 600-10. (Pubitemid 44464569)
37. Meltzer H (1997) Treatment resistant schizophrenia - the role of clozapine. Current Medical Research and Opinion 14: 1-20.
38. Meltzer H, Bastani B, Young Kwon K, et al (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 99: 68-72.
39. Moeller F, Chen Y, Steinberg J, et al (1995) Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Annals of Clinical Psychiatry 7: 167-73. (Pubitemid 26105849)
40. Mortimer AM, Singh P, Shepherd CJ, et al (2010) Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clinical Schizophrenia and Related Psychoses 4: 49-55.
41. Munro J, O'Sullivan D, Andrews C, et al (1999) Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. British Journal of Psychiatry 175: 576-80.
42. National Collaborating Centre for Mental Health (2009) Schizophrenia: Core Interventions in Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). National Institute for Health and Clinical Excellence.
43. Nielsen J, Dahm M, Lublin H, et al (2010) Psychiatrists' attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 24: 965-71.
44. Purcell H, Lewis S (2000) Postcode prescribing in psychiatry: clozapine in an English county. Psychiatric Bulletin 24: 420-2.
45. Rajagopal S (2005) Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgraduate Medical Journal 81: 545-6.
46. Rosenheck R, Cramer J, Xu W, et al (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337: 809-15. (Pubitemid 27391630)
47. Royal Australian and New Zealand College of Psychiatrists (2005) Clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 39: 1-30.
48. Schumacher J, Schulze TG, Wienker TF, et al (2000) Pharmacogenetic prediction of clozapine response. Lancet 356: 506-7.
49. Taylor D, Shapland L, Laverick G, et al (2000) Clozapine - a survey of patient perceptions. Psychiatric Bulletin 24: 450-2. (Pubitemid 32011030)
50. Taylor D, Young C, Paton C (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64: 30-4. (Pubitemid 36182226)
51. Taylor D, Paton C, Kapur S (2009) Clozapine - serious haematological and cardiovascular adverse effects. In The Maudsley Prescribing Guidelines, 10th Edition, 66-7. Informa Healthcare.
52. Tiihonen J, Lönnqvist J, Wahlbeck K, et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620-7.
53. Wahlbeck K, Cheine M, Essali A, et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and metaanalysis of randomised trials. American Journal of Psychiatry 156: 990-9. (Pubitemid 29302789)
54. Waserman J, Criollo M (2000) Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatric Services 51: 666-8. (Pubitemid 30256646)
55. Whiskey E, Wykes T, Duncan-McConnell D, et al (2003) Continuation of clozapine treatment: practice makes perfect. Psychiatric Bulletin 27: 211-3. (Pubitemid 36681906)
56. Woodall AA, Menkes DB, Trevelyan TR, et al (2004) A study of clozapine and long-term hospitalisation rates. Psychiatric Bulletin 28: 285-8. (Pubitemid 39144914)